July 31 (Reuters) -
RADELLA PHARMACEUTICALS ANNOUNCES NEW OBESITY TRIAL DATA SHOWING STATISTICALLY SIGNIFICANT WEIGHT LOSS AND BROADER CARDIOMETABOLIC BENEFITS
RADELLA PHARMACEUTICALS: PHASE 1B CLINICAL TRIAL OF MD-18 TARGETING OBESITY AND TYPE 2 DIABETES MET ITS OBJECTIVES